Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Current Hematologic Malignancy Reports|October 26, 2013
Multiple myeloma: Defining the high-risk patient and determining the optimal treatment strategyJordan Schecter, Suzanne Lentzsch
Blood Reviews|December 6, 2011
MDS: Refining existing therapy through improved biologic insightsJordan Schecter, Naomi Galili, Azra Raza
Human Pathology|February 1, 2013
Lymphoid follicle colonization by Bcl-2(bright+)CD10(+) B-cells ("follicular lymphoma in situ") at nodal and extranodal sites can be a manifestation of follicular homing of lymphomaJohn C Lee, Daniela Hoehn, Jordan Schecter, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 24, 2021
Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple MyelomaYael C Cohen, Albert Oriol, Ka Lung Wu, et al.
Advances in Therapy|October 31, 2018
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple MyelomaXu Steven Xu, Meletios A Dimopoulos, Pieter Sonneveld, et al.
Blood|May 23, 2019
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myelomaAjai Chari, Joaquín Martinez-Lopez, María-Victoria Mateos, et al.
The New England Journal of Medicine|August 25, 2016
Daratumumab, Bortezomib, and Dexamethasone for Multiple MyelomaAntonio Palumbo, Asher Chanan-Khan, Katja Weisel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2025
Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized TrialsQian Shi, Bruno Paiva, Levi D Pederson, et al.
Lancet (London, England)|June 8, 2019
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 studyPhilippe Moreau, Michel Attal, Cyrille Hulin, et al.
Pageof 1